Meta-Analysis of the Effects of Three-Dimensional Visualized Medical Techniques Hepatectomy for Liver Cancer with and Without the Treatment of Sorafenib

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2022 Sep 23

PMID 36147647

Authors

Lei Zeng

Yuming Zhu

Peng Guo

Affiliations

Soon will be listed here.

Abstract

Background: The application of medical image three-dimensional (3D) reconstruction technology can provide intuitive 3D image data support for accurate preoperative evaluation, surgical planning, and operation safety. However, there is still a lack of high-quality evidence to support whether 3D reconstruction technology is more advantageous in liver resection. Therefore, this study systematically evaluated the clinical effects of 3D reconstruction and two-dimensional (2D) image-assisted hepatectomy.

Methods: Databases were searched to collect published clinical studies on 3D reconstruction technology and 2D image-assisted liver resection. Data were extracted from the database construction to March 2022 and the risk of bias in the included studies was evaluated. Meta-analysis was performed using RevMan5.3 software.

Results: A total of 13 clinical studies were included, including 1616 patients, 795 in the 2D group and 819 in the 3D group. The meta-analysis showed that the incidence of postoperative complications was lower in the 3D group than in the 2D group (OR = 0.64, 95% CI = 0.49-0.83, =0.001) and also reduced operation time (SMD = -0.51, 95% CI = -0.74∼-0.27, < 0.0001), decreased intraoperative blood loss (SMD = -63.85, 95% CI = -98.66-29.04, =0.0003), decreased incidence of postoperative liver failure (OR = 2.42, 95% CI = 0.99-5.95, =0.05), decreased postoperative recurrence rate (OR = 0.29, 95% CI = 0.16-0.53, < 0.0001), and increased postoperative survival rate (OR = 2.19, 95% CI = 1.49-3.23, < 0.0001).

Conclusions: Current data suggest that 3D reconstruction-assisted hepatectomy can reduce intraoperative blood loss, postoperative complications, and recurrence, and improve postoperative survival. Therefore, the 3D reconstruction technique is worthy of application and promotion in assisted liver resection.

References

Fujiya K, Kumamaru H, Fujiwara Y, Miyata H, Tsuburaya A, Kodera Y . Preoperative risk factors for postoperative intra-abdominal infectious complication after gastrectomy for gastric cancer using a Japanese web-based nationwide database. Gastric Cancer. 2020; 24(1):205-213. DOI: 10.1007/s10120-020-01083-3. View

Leong T, Smithers B, Haustermans K, Michael M, Gebski V, Miller D . TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017; 24(8):2252-2258. DOI: 10.1245/s10434-017-5830-6. View

In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T . Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017; 24(12):3683-3691. DOI: 10.1245/s10434-017-6078-x. View

Du C, Li J, Zhang B, Feng W, Zhang T, Li D . Intraoperative navigation system with a multi-modality fusion of 3D virtual model and laparoscopic real-time images in laparoscopic pancreatic surgery: a preclinical study. BMC Surg. 2022; 22(1):139. PMC: 9004060. DOI: 10.1186/s12893-022-01585-0. View

Mohamed Abd Elaziz L, Salah T, Gharib F . The role of neoadjuvant FLOT chemotherapy with and without omega 3 in locally advanced gastric carcinoma. J BUON. 2021; 25(6):2672-2677. View

Smyth E, Nilsson M, Grabsch H, van Grieken N, Lordick F . Gastric cancer. Lancet. 2020; 396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5. View

Kitano S, Iso Y, Moriyama M, Sugimachi K . Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc. 1994; 4(2):146-8. View

Kashihara H, Shimada M, Yoshikawa K, Higashijima J, Tokunaga T, Nishi M . Risk factors for recurrence of gastric cancer after curative laparoscopic gastrectomy. J Med Invest. 2017; 64(1.2):79-84. DOI: 10.2152/jmi.64.79. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma.... Lancet. 2019; 393(10184):1948-1957. DOI: 10.1016/S0140-6736(18)32557-1. View

11.

Hugen S, Thomas R, German A, Burgener I, Mandigers P . Gastric carcinoma in canines and humans, a review. Vet Comp Oncol. 2016; 15(3):692-705. DOI: 10.1111/vco.12249. View

12.

Zeng F, Chen L, Liao M, Chen B, Long J, Wu W . Laparoscopic versus open gastrectomy for gastric cancer. World J Surg Oncol. 2020; 18(1):20. PMC: 6986035. DOI: 10.1186/s12957-020-1795-1. View

13.

Wang N, Zhou A, Jin J, Huang H, Zhang Y, Chen Y . Open vs. laparoscopic surgery for locally advanced gastric cancer after neoadjuvant therapy: Short-term and long-term survival outcomes. Oncol Lett. 2020; 20(1):861-867. PMC: 7285756. DOI: 10.3892/ol.2020.11626. View

14.

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

15.

Kodera Y . Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017; 47(8):899-907. DOI: 10.1007/s00595-017-1473-2. View

16.

Cabral F, Ramos P, Monteiro C, Casaca R, Pinto I, Abecasis N . Impact of perioperative chemotherapy on postoperative morbidity after gastrectomy for gastric cancer. Cir Esp (Engl Ed). 2021; 99(7):521-526. DOI: 10.1016/j.cireng.2021.07.007. View

17.

Huang C, Yu F, Zhao G, Xia X . Postoperative quality of life after laparoscopy-assisted pylorus-preserving gastrectomy compared with laparoscopy-assisted distal gastrectomy for early gastric cancer. J Gastroenterol Hepatol. 2020; 35(10):1712-1719. DOI: 10.1111/jgh.14985. View

18.

Lee H, Hyung W, Yang H, Han S, Park Y, An J . Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT). Ann Surg. 2019; 270(6):983-991. DOI: 10.1097/SLA.0000000000003217. View

19.

Fujisaki M, Mitsumori N, Shinohara T, Takahashi N, Aoki H, Nyumura Y . Short- and long-term outcomes of laparoscopic versus open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy. Surg Endosc. 2020; 35(4):1682-1690. DOI: 10.1007/s00464-020-07552-1. View

20.

Khaled I, Priego P, Soliman H, Faisal M, Saad Ahmed I . Oncological outcomes of laparoscopic versus open gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a retrospective multicenter study. World J Surg Oncol. 2021; 19(1):206. PMC: 8272390. DOI: 10.1186/s12957-021-02322-2. View